Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables turns negative
Q3 FY2026 accounts payables was -$8.26M, compared with $1.99M a year earlier. Trailing-twelve-month accounts payables was -$15.8M. Over 3 fiscal years it compounded at +45.9% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$8.26M or moves back toward the trailing-twelve-month quarterly average of -$3.95M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 12.1M USD
- Year-over-year change
- +80.2%
- 4-year CAGR
- +13.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.1M | +80.2% |
| FY2024 | 2024-12-31 | 6.71M | +175.8% |
| FY2023 | 2023-12-31 | (8.86M) | -327.5% |
| FY2022 | 2022-12-31 | 3.89M | -46.4% |
| FY2021 | 2021-12-31 | 7.27M | — |
Accounts Payables vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 accounts payables of $15.8M is the 4th largest of the 10 companies compared; the peer median is $3.67M.
- Its year-over-year change of -200.0% is the 8th highest of 9, against a peer median of +150.0%.
- Over three fiscal years its annual growth of +45.9% compares with a peer median of +8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $54M | — | — | 1.5% | |
| LTM Jun 2026 | $25.76M | +74.1% | +8.6% | 3.1% | |
| LTM Jun 2026 | $24.47M | +11282.3% | — | 2.1% | |
| LTM Sep 2026 | $15.8M | -200.0% | +45.9% | — | |
| LTM Jun 2026 | $12.66M | -141.8% | — | 1.6% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.34M | +345.5% | — | 21.7% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4M | +845.6% | — | — |
| LTM Sep 2026 | $3.67M | +225.9% | -11.9% | — | |
| LTM Jun 2026 | $3.38M | +7.9% | — | 93.6% | |
| LTM Dec 2025 | $1.93M | -801.1% | +80.5% | — | |
| Peer median (excluding PRAX) | $3.67M | +150.0% | +8.6% | 2.6% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| Deferred Income Tax | 2.09M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Change in Working Capital | 16.13M | (1.78M) | (13.03M) | 10.92M | 22.68M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.27M | 3.89M | (8.86M) | 6.71M | 12.1M |
| Other Working Capital | 8.87M | (5.67M) | (4.17M) | 4.21M | 10.58M |
| Other Non-Cash Items | 1.41M | 1.76M | (121K) | (1.58M) | (2.56M) |
| Operating Cash Flow | (124.55M) | (185.04M) | (111.14M) | (131.76M) | (249.07M) |
| Capital Expenditures | (1.05M) | (444K) | (50K) | 0 | (56K) |
| Acquisitions (Net) | 139.47M | (97.33M) | 0 | 0 | 0 |
| Purchases of Investments | (164.17M) | (83.02M) | 0 | (371.52M) | (623.81M) |
| Sales of Investments | 24.7M | 180.36M | 39M | 123.03M | 312.72M |
| Other Investing Activities | (139.47M) | 97.33M | 0 | 0 | 0 |
| Investing Cash Flow | (140.52M) | 96.89M | 38.95M | (248.49M) | (311.15M) |
| Debt Repayment | (763K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.64M | 904K | 279K | 2.33M | (2.09M) |
| Financing Cash Flow | 107.59M | 10.47M | 91.87M | 514.32M | 702.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (157.49M) | (77.69M) | 19.69M | 134.07M | 141.96M |
| Free Cash Flow | (125.6M) | (185.49M) | (111.19M) | (131.76M) | (249.12M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.